Matches in SemOpenAlex for { <https://semopenalex.org/work/W2436231368> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2436231368 endingPage "7" @default.
- W2436231368 startingPage "590" @default.
- W2436231368 abstract "Treatment of Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL) is still unsatisfactory in patients resistant to primary therapy or those with early relapses. The objective of the trial was to test whether salvage regimens based on a combination of iphosphamide and etopozide have a sufficient anti-lymphoma effect, while the toxicity is still acceptable, and in conjunction with growth factors as satisfactory mobilizing potential for the collection of peripheral stem cells (PBSC).A group of 40 patients with relapsing and/or primary therapy resisting lymphomas (14 NHL, 26 HD) were treated by life saving or stimulating chemotherapy VIM (etopozide, iphosphamide, methotrexate) and MINE (iphosphamide mitoxanthrone, etopozide; mostly NHL). If the response to these regimes was inadequate, to some patients in addition mini (dexa) regimes were administered, BEAM and DHAP resp., with the objective to achieve maximum reduction of the tumourous mass before high-dosage treatment with the support of autologous PBSC. The authors administered 119 cycles of salvage chemotherapy (51 VIM, 46 MINE, 22 mini-dexa-BEAM and DHAP). The toxicity of chemotherapy and the therapeutic response were evaluated according to WHO criteria. The toxicity of VIM and MINE, with the exception for mobilization of desirable transient leukopenia, was not serious. During stimulation of PBSC on average three leukophereses were made and on average 9.9. 10(6) CD34+ cells/kg body weight of the patient were obtained and 53.2. 10(4) CFU-GM/kg (VIM), and 13.5. 10(6) CD34+ cells/kg 53.4. 10(4) CFU-GM/kg (MINE) resp. A total of 64% (MINE) and 61% (VIM) therapeutic responses were obtained, 14% (MINE) and 26% (VIM) complete remissions and 50% (MINE) and 35% (VIM) partial remissions.Life saving regimes, VIM and MINE, have a good antilymphoma activity, low toxicity and in combination with growth factors (filgrastim) they ensure a good collection of PBSC. As compared with other regimens, in particular for stimulation, VIM and MINE appear to be better." @default.
- W2436231368 created "2016-06-24" @default.
- W2436231368 creator A5007369156 @default.
- W2436231368 creator A5008998843 @default.
- W2436231368 creator A5010552286 @default.
- W2436231368 creator A5010576561 @default.
- W2436231368 creator A5024897140 @default.
- W2436231368 creator A5032446221 @default.
- W2436231368 creator A5040644955 @default.
- W2436231368 creator A5041156818 @default.
- W2436231368 creator A5044586150 @default.
- W2436231368 creator A5047489551 @default.
- W2436231368 creator A5054654885 @default.
- W2436231368 creator A5060602062 @default.
- W2436231368 creator A5067918308 @default.
- W2436231368 creator A5087700915 @default.
- W2436231368 creator A5091155004 @default.
- W2436231368 date "1998-10-05" @default.
- W2436231368 modified "2023-09-23" @default.
- W2436231368 title "[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells]." @default.
- W2436231368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9818471" @default.
- W2436231368 hasPublicationYear "1998" @default.
- W2436231368 type Work @default.
- W2436231368 sameAs 2436231368 @default.
- W2436231368 citedByCount "0" @default.
- W2436231368 crossrefType "journal-article" @default.
- W2436231368 hasAuthorship W2436231368A5007369156 @default.
- W2436231368 hasAuthorship W2436231368A5008998843 @default.
- W2436231368 hasAuthorship W2436231368A5010552286 @default.
- W2436231368 hasAuthorship W2436231368A5010576561 @default.
- W2436231368 hasAuthorship W2436231368A5024897140 @default.
- W2436231368 hasAuthorship W2436231368A5032446221 @default.
- W2436231368 hasAuthorship W2436231368A5040644955 @default.
- W2436231368 hasAuthorship W2436231368A5041156818 @default.
- W2436231368 hasAuthorship W2436231368A5044586150 @default.
- W2436231368 hasAuthorship W2436231368A5047489551 @default.
- W2436231368 hasAuthorship W2436231368A5054654885 @default.
- W2436231368 hasAuthorship W2436231368A5060602062 @default.
- W2436231368 hasAuthorship W2436231368A5067918308 @default.
- W2436231368 hasAuthorship W2436231368A5087700915 @default.
- W2436231368 hasAuthorship W2436231368A5091155004 @default.
- W2436231368 hasConcept C126322002 @default.
- W2436231368 hasConcept C141071460 @default.
- W2436231368 hasConcept C143998085 @default.
- W2436231368 hasConcept C2776694085 @default.
- W2436231368 hasConcept C2777506904 @default.
- W2436231368 hasConcept C2778119113 @default.
- W2436231368 hasConcept C2779338263 @default.
- W2436231368 hasConcept C2780873365 @default.
- W2436231368 hasConcept C29730261 @default.
- W2436231368 hasConcept C71924100 @default.
- W2436231368 hasConcept C90924648 @default.
- W2436231368 hasConceptScore W2436231368C126322002 @default.
- W2436231368 hasConceptScore W2436231368C141071460 @default.
- W2436231368 hasConceptScore W2436231368C143998085 @default.
- W2436231368 hasConceptScore W2436231368C2776694085 @default.
- W2436231368 hasConceptScore W2436231368C2777506904 @default.
- W2436231368 hasConceptScore W2436231368C2778119113 @default.
- W2436231368 hasConceptScore W2436231368C2779338263 @default.
- W2436231368 hasConceptScore W2436231368C2780873365 @default.
- W2436231368 hasConceptScore W2436231368C29730261 @default.
- W2436231368 hasConceptScore W2436231368C71924100 @default.
- W2436231368 hasConceptScore W2436231368C90924648 @default.
- W2436231368 hasIssue "19" @default.
- W2436231368 hasLocation W24362313681 @default.
- W2436231368 hasOpenAccess W2436231368 @default.
- W2436231368 hasPrimaryLocation W24362313681 @default.
- W2436231368 hasRelatedWork W2003208630 @default.
- W2436231368 hasRelatedWork W2033860338 @default.
- W2436231368 hasRelatedWork W2041896056 @default.
- W2436231368 hasRelatedWork W2270672625 @default.
- W2436231368 hasRelatedWork W2349845124 @default.
- W2436231368 hasRelatedWork W2410052619 @default.
- W2436231368 hasRelatedWork W2415771749 @default.
- W2436231368 hasRelatedWork W4241272925 @default.
- W2436231368 hasRelatedWork W6933653 @default.
- W2436231368 hasRelatedWork W802126212 @default.
- W2436231368 hasVolume "137" @default.
- W2436231368 isParatext "false" @default.
- W2436231368 isRetracted "false" @default.
- W2436231368 magId "2436231368" @default.
- W2436231368 workType "article" @default.